Strides Arcolab’s two promoter group companies, Agnus Holdings Pvt Ltd and Chayadeep Properties Pvt Ltd, have pledged 14 lakh equity shares of the company between June 17 and 24, 2011.
While Agnus Holdings Pvt Ltd pledged 12.50 lakh equity shares from June 17-24, Chayadeep Properties Pvt Ltd pledged 1.5 lakh shares on June 17, the company said in a BSE filing on Friday.
Meanwhile, Onco Therapies Limited (OTL), a division of Agila, a wholly owned subsidiary of Strides Arcolab Ltd, on July 01, 2011 announced that it has received European approval for its oral dosage oncology facility (tablet and hard gelatine capsules) in Bangalore.
The injectable facility within the oncology complex has already been approved by all major regulatory agencies. The facility is now amongst a few European approved Oral dosage oncology plants worldwide.
The company expects to commercialise two products in Europe during Q3 2011.
Commenting on this development, Venkat Iyer, CEO, Agila Specialties, said: “The approval will further help consolidate our global trategy of emerging as a leading provider of oncology drugs. The approval is also a testimony to the high standards of quality, compliance and containment practices put in place by Strides.”
The state-of-the-art oncology complex which was established in 2009 manufactures injectables, oral products (tablets and softgels) in the oncology domain. It has been built to the most exacting standards, meeting the requirements of regulatory authorities in the most stringent global markets and is already approved by all other major regulatory authorities allowing the company to sell globally.
